Entries by Mithra Pharmaceuticals

Nomination of Christophe Maréchal as interim CEO

Liege, Belgium, 21 January 2021 – 22:00 CET – Meeting this Thursday evening, the Board of Directors of Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, took note of the arrest warrant issued against François Fornieri in connection with duties he previously performed in a company not related to Mithra.

Mithra Announces 2021 Financial Calendar

Liege, Belgium, 12 January 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces its financial calendar for 2021 : 9 March 2021 : 2020 Full Year Results 20 April 2021 : 2020 Annual Report 20 May 2021 : Annual General Shareholders Meeting 24 September 2021 : 2021 Interim […]

Richter and Mithra strengthen their partnership and signed a license and supply agreement for the commercialization of Estelle® to Latin America

Budapest, Hungary – Liege, Belgium – 23 December 2020 – 7:30 CET –Gedeon Richter Plc. (‘Richter’) and Estetra S.A, the wholly owned subsidiary of Mithra (Euronext Brussels: MITRA), today announced that they have extended their partnership and signed a license and supply agreement for the commercialization of Estelle®, a novel 15 mg estetrol (E4) / […]

Mithra Announces Positive DSMB Safety Review and Continuation of its Phase III Clinical Program Donesta® in menopause

Independent Data Safety Monitoring Board (DSMB) confirms the acceptable safety profile of Donesta® and recommends to continue the Phase III Clinical Program as planned On track to target marketing authorization in 2023 Consolidation of business development strategy of Donesta® by successful major funding transactions in 2020 Liege, Belgium, 16 December 2020 – 7:30 CET – […]

Mithra announces final terms of its offering of EUR 125 million convertible bonds due 2025

Liege, Belgium, 10 December 2020 – 20:30 CET – With reference to the two press releases issued on 10 December 2020 at 08:00 and 17:30 CET respectively, Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces the final terms of the offering (the “Offering”) of EUR 125 […]

Mithra launches an offering of up to EUR 150 million convertible bonds due 2025

Liege, Belgium, 10 December 2020 – 08:00 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, announces today the launch of an offering (the “Offering”) of senior unsecured convertible bonds due 17 December 2025 (the “Bonds”), for an initial aggregate principal amount of EUR 125 million […]

Scientific community convinced of Estetrol’s potential for women’s health

At the 19th ISGE Congress, Mithra and Gedeon Richter presented the clinical results of Estelle® to an international scientific audience While Estetrol (E4) has recently been designated as a “New Active Substance” by the European Medicines Agency (EMA), doctors there have confirmed their strong interest in the use of E4 in contraception. Liege, Belgium, 3 […]

Estetrol recognized as a “New Active Substance” by the European Medicines Agency (EMA)

This is the first time in more than 80 years that a new estrogen has been introduced in the field of contraception. Liège, Belgium, 25 November 2020 – 7:30 CET – Mithra, a company dedicated to Women’s Health (Euronext Brussels: MITRA), today announces that the European Medicines Agency (EMA) has designated Estetrol monohydrate (E4) as […]